TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00900796

Intervention type: OTHER
Intervention: Treatment switching
Description: If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
Study: NCT01617044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02688413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MindMotionPRO
Description: The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Prescribed Exercises
Description: GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
Study: NCT04452643

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BACMUNE (MV130)
Description: BACMUNE (MV130) is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a solution on sodium chloride at 0.9%
Study: NCT03698734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evening primrose oil(EPO)
Description: primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
Study: NCT05252689

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: monolithic zirconia single posterior crowns with deep chamfer finish line
Description: deep chamfer of 1 mm average thickness for cervical finish line, a convergence angle of 6-12° on each side and up to 20° total, in some studies, is acceptable and occlusal reduction of 1,5-2 mm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monolithic zirconia single posterior crowns with vertical finish line
Description: using special round-ended 2 degrees tapered diamond burs a non-working tip (batt bur). It has coronal diameter of 1.2 mm, apical diameter of 0.7 mm, and non- cutting end of 1 mm, which reduces or avoids damage to the connective attachment and allows a tooth-guided preparation procedure
Study: NCT03947541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracolumbosacral (TLSO) brace
Description: Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Bracing
Description: Participants will not wear a brace in the study.
Study: NCT03094130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT03741361

Intervention type: OTHER
Intervention: anxiety and depression
Description: Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
Study: NCT01713634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preflight
Description: 4-d controlled diet sessions will occur twice before flight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preflight
Description: 4-d controlled diet sessions will occur twice before flight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-flight
Description: 4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-flight
Description: 4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
Study: NCT01839474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
Study: NCT02939521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT02852226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre Exposure Prophylaxis
Description: Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Characteristics of women who enroll
Description: The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: referral sources of women who enroll
Description: Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
Study: NCT00811252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules; daily; orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets; daily; orally

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: encapsulated tablets; daily; orally
Study: NCT03420638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjunct Exparel (bupivacaine liposome suspension 1.3%)
Description: After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% \[13.3 mg/mL\] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
Study: NCT03456011

Intervention type: OTHER
Group type: OTHER
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture gold semi permanent needles
Study: NCT05293418

Intervention type: OTHER
Intervention: data collection
Description: data collection from medical records and the microbiological surveillance system of the enrolled patients
Study: NCT03014648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
Study: NCT03553173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: So-Lo-Mo
Description: So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
Study: NCT03500341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00014
Description: Noninvasive pulse oximeter sensor
Study: NCT04394962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Patients randomized to the study group, will be provided with the VR headset and sensors. The VR exposure will take place before the ET procedure, during their routine pre-transfer waiting period, in a private room. The patient will be able to choose between three different calming VR environments (3 scenes: beach sunset, palm tree patio or redwood forest) and will be exposed to the chosen VR environment for a continuous duration of 15-30 minutes. The VR exposure will be passive, and the patient can control her observation inside the environment by herself, simply by moving her head. During this period, at any time and for any reason, the patient can discontinue the use of the VR session simply by self-removing the helmet
Study: NCT02017262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management group
Description: 8 weekly sessions of group self-management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
Study: NCT03917147

Intervention type: PROCEDURE
Intervention: Office Hysteroscopy
Description: Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.

Intervention type: PROCEDURE
Intervention: Office Hysteroscopy
Description: Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.

Intervention type: PROCEDURE
Intervention: Office Hysteroscopy
Description: Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.

Intervention type: PROCEDURE
Intervention: Office Hysteroscopy
Description: Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
Study: NCT02169063

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon-11 acetate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 sodium fluoride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo 11C-acetate and 18F-fluoride PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01593852

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Advanced image processing
Description: Acquisition of x-ray images with reduced X-ray dose and advanced image processing

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Regular image processing
Description: Acquisition of x-ray images with regular X-ray dose and regular image processing
Study: NCT04649593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Samarin
Description: Half of the group with a high AFL value will have a glass of Samarin to drink
Study: NCT03590808

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination
Description: Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
Study: NCT03059186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude diary
Description: The intervention involves keeping a record of three things that the individual feels grateful for during that day.~This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week.
Study: NCT03289884

Intervention type: OTHER
Intervention: MRI scan (not involving ionising radiation)
Description: The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Intervention type: OTHER
Intervention: MRI scan (not involving ionising radiation)
Description: The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Intervention type: OTHER
Intervention: Ultrasound scan (not involving ionising radiation)
Description: The US scan will be conducted by a nominated researcher

Intervention type: OTHER
Intervention: Ultrasound scan (not involving ionising radiation)
Description: The US scan will be conducted by a nominated researcher

Intervention type: OTHER
Intervention: Ex vivo MRI scan of cyst fluid sample
Description: The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher

Intervention type: OTHER
Intervention: Aspiration of cyst fluid
Description: For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist

Intervention type: OTHER
Intervention: Blood test for confirmation of serum IgG levels consistent with hydatid infection
Description: The blood sample will be drawn by a member of the clinical team
Study: NCT01115647

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food (RUTF)
Description: A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CBS++
Description: CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
Study: NCT02916329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
Description: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
Study: NCT01115647

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCC
Description: Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
Study: NCT01013077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optive
Description: Use a minimum of 2 drops per day for 1 month.
Study: NCT03553173

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological advice
Description: Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
Study: NCT02916329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
Description: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
Description: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
Description: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907
Description: 68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
Study: NCT00785941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: Cohort 1~6 mg/kg I.V., once every other week for 4 weeks
Study: NCT01013077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soothe
Description: Use a minimum of 2 drops per day for 1 month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Emulsion
Description: Use a minimum of 2 drops per day for 1 month.
Study: NCT04230525

Intervention type: DIAGNOSTIC_TEST
Intervention: non invasive whole body bioimpedence system
Description: Noninvasive hemodynamic changes will be observed by using whole-body impedance method urgent or elective cesarian section patients under general anesthesia. The whole-body bioimpedance method will be used to monitör the hemodynamic changes non invasively. This method can evaluate such as cardiac output, cardiac index, stroke volüme, stroke index, stroke volüme variations, cardiac reserve, etc. Parameters with a completely noninvasive method by using only electrots. The device consists of a laptop, a software which calculates cardiac parameters and two electrodes. The measurement is done by the following process: one of these electrodes, which looks like ECG electrodes, is stuck to the wrist and the other one to the opposite ankle or each one to two wrists.
Study: NCT00178802

Intervention type: OTHER
Group type: OTHER
Intervention: thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
Description: 5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol
Study: NCT01327391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On line Hemodiafiltration
Description: 3 sessions/week; 3-4 hours per session

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hemodialysis
Description: 3 sessions/week; 3-4 hours per session; high flux dialyzers
Study: NCT04183673

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: 5 days per week, 3 weeks, sessions of usual rehabilitation